Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · Real-Time Price · USD
0.292
-0.005 (-1.75%)
At close: Nov 4, 2024, 4:00 PM
0.291
-0.001 (-0.45%)
After-hours: Nov 4, 2024, 7:19 PM EST
Cara Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cara Therapeutics stock have an average target of 1.00, which predicts an increase of 242.70% from the current stock price of 0.29.
Analyst Consensus: Hold
* Price targets were last updated on Jun 13, 2024.
Analyst Ratings
The average analyst rating for CARA stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $10 → $1 | Strong Buy → Hold | Downgrades | $10 → $1 | +242.70% | Jun 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 13, 2024 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +1,613.50% | May 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3.6 | Strong Buy | Reiterates | $3.6 | +1,133.72% | May 15, 2024 |
Financial Forecast
Revenue This Year
6.76M
from 20.97M
Decreased by -67.77%
Revenue Next Year
6.55M
from 6.76M
Decreased by -3.00%
EPS This Year
-1.31
from -2.19
EPS Next Year
-0.79
from -1.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 10.4M | 13.2M | 17.4M | ||
| Avg | 6.8M | 6.6M | 7.4M | ||
| Low | 4.7M | 3.1M | 1.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -50.2% | 95.1% | 165.4% | ||
| Avg | -67.8% | -3.0% | 13.2% | ||
| Low | -77.6% | -54.7% | -77.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.18 | -0.36 | -0.34 | ||
| Avg | -1.31 | -0.79 | -0.65 | ||
| Low | -1.35 | -1.11 | -1.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.